Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Revenue of LEQEMBI (Preliminary Basis)
PRISM BioLab Slips on Profit-Taking Despite Joint Presentation with Eisai on E7386 Preclinical Data◇
Notice of Nominees for Directors
Eisai Announces Appointment of Corporate Officers
FY 2025 (Ending March 31,2026) Third Quarter Financial Results Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Nine-Month Period Ended December 31, 2025
Eisai, Apr-Dec (Cumulative 3Q) Net Income Decreases by 8%, Exceeds Full-Year Plan
Revenue of LEQEMBI (Preliminary Basis)
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
Eisai, Jul-Sep (2Q) Net Income Decreases by 9%
Financial Results for the Six-Month Period Ended September 30,2025 Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2025
Revenue of LEQEMBI (Preliminary Basis)
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2025
Eisai, Apr-Jun (1Q) Net Income Increases by 37%
FY 2025 (Ending March 31,2026) First Quarter Financial Results Reference Data
Revenue of LEQEMBI (Preliminary Basis)
Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.